论文部分内容阅读
一、抗菌作用氨曲南(Aztreonam)是第一个临床应用的单环类β-内酰胺抗生素。本品对革兰氏阳性需氧菌的作用很弱或没有作用;对50～90%的金黄色葡萄球菌、β-溶血性链球菌和非溶血性链球菌及肠球菌的MIC为64～>128 mg/L;对化脓性链球菌的MIC是8～128 mg/L。对革兰氏阴性需氧菌的作用很强。肠杆菌属中大肠杆菌,克雷伯氏肺炎杆菌,变形杆菌包括奇异变形杆菌、普通变形杆菌、摩根氏变形杆菌和粘质沙雷氏杆菌在氨曲南浓度为1.6 mg/L或更低时即可被抑制。与第三代头孢和其他抗生素相比较,本品抗肠杆菌属的作用一般与头孢噻肟和头孢
First, the antibacterial activity aztreonam (Aztreonam) is the first clinical application of monocyclic β-lactam antibiotics. This product is weak or no effect on Gram-positive aerobic bacteria; for 50 to 90% of Staphylococcus aureus, β-hemolytic streptococcus and non-hemolytic streptococcus and Enterococcus MIC = 64 ~ 128 mg / L; for S. pyogenes, the MIC is 8 to 128 mg / L. Gram-negative aerobic bacteria have a strong role. Enterobacter, Escherichia coli, Klebsiella pneumoniae and Proteus, including Proteus mirabilis, Proteus vulgaris, Proteus morganii and Serratia marcescens At aztreonam concentrations of 1.6 mg / L or less Can be suppressed. Compared with the third generation of cephalosporins and other antibiotics, the role of anti-Enterobacter spp generally cefotaxime and cephalosporin